FrostPharma organisation announcement

During her tenure as CEO for FrostPharma AB, Cecilia Bröms-Thell has invested and prepared the FrostPharma business for accelerated growth while securing solid performance of the in-line portfolio. The Regulatory framework and the Commercial capabilities have been strengthened and FrostPharma is now in a position to leverage and maximise its pipe-line opportunities. Cecilia Bröms-Thell has however recently decided to explore new opportunities outside of FrostPharma why she has resigned as CEO. For a period of time Cecilia has however agreed to stay on as Chief Commercial Officer effective 1 january 2022. In this new role Cecilia Bröms-Thell will continue to strengthen the FrostPharma capabilities. “On behalf of FrostPharma and the Board I want to thank Cecilia Bröms-Thell for her significant contribution to the FrostPharma business as CEO and wish her good luck in her new role within FrostPharma as Chief Commercial Officer and later in her new role outside of Frost.”

From the 1st of January 2022 Fredrik Andersch take the role of FrostPharma CEO. Fredrik Andersch brings extensive international experience to FrostPharma from senior business positions at pharmaceutical companies such as AstraZeneca and Meda. Fredrik Andersch has a proven track-record of delivering strong growth through complex organisations both in a Nordic and international setting, such as Europe and Asia. With his background Fredrik Andersch also strengthen FrostPharma business development capabilities. The experience to drive growth through both portfolio and geographic expansion will further strengthen FrostPharma in its growth journey. As Fredrik consulted for FrostPharma in 2021 he has in-depth understanding of the organisation and business model, which secure business continuity during the transition. “On behalf of FrostPharma and the Board I want to wish Fredrik Andersch good luck in his role of CEO, and I look forward to working with him going forward.”

About Frost Pharma AB

FrostPharma AB is an entrepreneurial Swedish pharmaceutical company specialized in commercialization of products creating value. Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, covering all Nordic countries and beyond. Key to success is the ability to match specific patient- and healthcare needs with relevant products in relation to our extensive in-house commercialization competence.

Tomas Guinchard

Chairman of the Board

Djupdykning - återvinningsbara doshjälpmedel

Henrik Alfredsson är Frost's vägvisare inom att ta fram återvinningsbara produkter. Nedan berättar han mer om våra doshjälpmedel i 100% återvinningsbar bioplast.

Vad är skillnaden på bioplast och vanlig plast som många artiklar är gjorda av idag?

De doshjälpmedel som är tillverkade av bioplast innehåller majsstärkelse för att minska andelen plast och därmed minska CO2-utsläpp. Vi använder den råvara som har högsta möjliga andel förnybart material för produktion.

På vilket sätt är våra doshjälpmedel ett bättre alternativ ur miljösynpunkt?

De är tillverkade i Sverige, CE-märkta, och kan återvinnas då de inte innehåller giftiga färger som förhindrar återvinning. Vi har även minskat mängden onödigt emballage som plastpåsar och använder miljövänliga kartonger för transport.

Vilka är de största fördelarna med våra doshjälpmedel i bioplast?

De är bättre för miljön och kan återvinnas. Även minskat utsläpp då de slipper transporteras från Kina där många alternativ kommer ifrån.

Vart hittar man våra doshjälpmedel?

Produkterna finns ute på merparten av samtliga apotek i Sverige och går även att beställa via Oriola. För övriga inköpskanaler kan ni kontakta oss direkt på info@frostpharma.com.

FrostPharma wins two national tenders in Norway

FrostPharma is proud and pleased to announce that the company has been successful in the tender bidding process in Norway. The company has been notified of winning two national tender contracts in two different therapeutic areas, starting Feb 1, 2022 and running for two years with option to prolong another two years. This means that the health care providers and patients eligible for these specific treatments will have access to our value-added products throughout the tender contract period in Norway. The therapeutic areas in scope for these two treatments are sedation and anti-thrombotic treatment.